|
시장보고서
상품코드
2091777
항감염제 시장 규모, 점유율 및 성장 분석 : 약제 클래스별·작용기서별, 투여 경로별, 판매 채널별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)Anti Infective Drugs Market Size, Share, and Growth Analysis, By Drug Class Mechanism, By Route of Administration, By Sales Channel, By Distribution Channel, By Region - Industry Forecast 2026-2033 |
||||||
세계의 항감염제 시장 규모는 2024년에 1,126억 8,000만 달러로 평가되며, 2025년 1,200억 달러에서 2033년까지 1,986억 1,000만 달러로 확대하며, 예측 기간(2026-2033년)에 CAGR 6.5%로 성장할 것으로 전망되고 있습니다.
세계 항감염제 시장은 헬스케어 분야에서 매우 중요한 부문으로, 세균, 바이러스, 진균, 기생충에 의한 다양한 감염병의 예방 및 치료를 목적으로 하는 의약품에 초점을 맞추고 있습니다. 이 시장의 성장은 감염병 발생률 증가, 면역력이 약해진 고령 인구 증가, 그리고 감염 위험을 높이는 침습적 의료 시술의 이용 급증에 힘입어 이루어지고 있습니다. 항생제 내성(AMR)의 급증은 비용이 높음에도 불구하고 혁신적인 의약품에 대한 수요를 촉진하는 중요한 요인이 되고 있습니다. 각 제약사는 기존 약물의 효능이 점차 떨어지고 있는 상황에서 필수적인 신규 약물 계열의 연구개발에 막대한 투자를 하고 있습니다. AI를 활용한 신약 개발 기술의 발전은 의약품 개발 과정의 효율화, 비용 절감, 내성균에 대한 효과적인 치료법 개발 촉진을 통해 시장에 새로운 변화를 가져오고 있으며, 이를 통해 전 세계에서 큰 성장 기회를 창출하고 있습니다.
세계 항감염제 시장의 성장 요인
전 세계의 항감염제 수요는 전 세계 의료 시스템이 직면하고 있는 세균, 바이러스, 진균에 의한 감염병 유병률의 증가에 큰 영향을 받고 있습니다. 의료진이 점점 더 복잡해지는 내성 양상에 직면함에 따라 효과적인 치료 성과를 확보하기 위해 혁신적인 치료법에 대한 의존도가 높아지고 있습니다. 이러한 시급한 임상적 필요성으로 인해 제약 기업의 연구개발 투자가 활발해지고 있으며, 이는 제품 혁신의 가속화와 시장 진출 확대로 이어지고 있습니다. 그 결과, 병원 및 외래 진료 시설은 이러한 첨단 항감염 치료제의 도입을 우선시하고 있으며, 이는 다양한 지역과 치료 분야에서 지속적인 성장을 촉진하고, 나아가 시장의 지속적인 확장을 지원하고 있습니다.
세계 항감염제 시장의 제약 요인
전 세계 항감염제 시장은 항생제 내성의 확산으로 인해 중대한 과제에 직면해 있습니다. 이는 현행 치료법의 효과를 저해할 뿐만 아니라, 의료 종사자와 보험사 사이에 우려를 불러일으키고 있습니다. 내성으로 인해 이용 가능한 치료 옵션이 제한됨에 따라 임상의들은 더 오래되고 저렴한 약물로 전환할 가능성이 있으며, 이로 인해 혁신적인 제품에 대한 수요가 감소할 우려가 있습니다. 규제 당국은 승인 절차를 강화하거나 시판 후 감시를 엄격히 시행하는 방식에 대응할 가능성이 있으며, 그 결과 제약 기업 입장에서는 개발 기간이 길어지거나 비용이 증가할 수 있습니다. 이러한 복잡한 상황은 투자를 주저하게 만들고, 새로운 치료법의 도입을 저해하며, 시장 전체의 성장을 제한할 가능성이 있습니다. 이는 이해관계자들이 획기적인 치료법의 도입보다는 책임 있는 사용과 위험 최소화에 중점을 두기 때문입니다.
세계 항감염제 시장의 동향
전 세계 항감염제 시장에서는 약물의 작용 기전을 병원체의 유전자 프로파일 및 숙주의 바이오마커와 연계하는 개인 맞춤형 치료 전략을 중시하는 ‘정밀 의료’로의 뚜렷한 추세가 나타나고 있습니다. 이러한 변화는 첨단 염기서열 분석 기술과 신속한 진단 툴에 의해 촉진되고 있으며, 이를 통해 내성 균주를 조기에 식별하고 치료 접근법의 개인화를 촉진합니다. 그 결과, 임상의는 경험적 처방을 최소화할 수 있으며, 이는 환자의 예후 개선과 항감염제 제품의 수명 연장으로 이어집니다. 이에 따라 각 제약사는 전 세계에서 진화하는 헬스케어 수요와 공중보건 구상에 대응하기 위해 동반 진단에 대한 투자를 늘리고, 표적 치료제 개발을 추진하고 있습니다.
자주 묻는 질문
목차
서론
조사 방법
개요
시장 역학과 전망
주요 시장 인사이트
세계의 항감염제 시장 규모 : 약제 클래스별·작용기서별
세계의 항감염제 시장 규모 : 투여 경로별
세계의 항감염제 시장 규모 : 판매 채널별
세계의 항감염제 시장 규모 : 유통 채널별
세계의 항감염제 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSA 26.07.22Global Anti Infective Drugs Market size was valued at USD 112.68 Billion in 2024 and is poised to grow from USD 120.0 Billion in 2025 to USD 198.61 Billion by 2033, growing at a CAGR of 6.5% during the forecast period (2026-2033).
The global anti-infective drugs market is a pivotal segment of healthcare, focused on pharmaceuticals aimed at preventing and treating a multitude of infections from bacteria, viruses, fungi, and parasites. This market's growth is driven by the increasing incidence of infectious diseases, the elderly population with compromised immunity, and the soaring use of invasive medical procedures that elevate infection risks. The surge in antimicrobial resistance (AMR) is a key factor spurring demand for innovative agents despite their higher costs. Manufacturers are investing heavily in research for novel drug classes, which are crucial as older medications become ineffective. Advances in AI-driven drug discovery are further revolutionizing the market by streamlining the drug development process, lowering costs, and enhancing the creation of effective treatments for resistant strains, thereby fostering significant growth opportunities globally.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anti Infective Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Anti Infective Drugs Market Segments Analysis
Global anti infective drugs market is segmented by drug class mechanism, route of administration, sales channel, distribution channel and region. Based on drug class mechanism, the market is segmented into Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs and Antiparasitic Drugs. Based on route of administration, the market is segmented into Oral Formulations, Parenteral Injections and Topical Formulations. Based on sales channel, the market is segmented into Online and Offline. Based on distribution channel, the market is segmented into Direct and Indirect. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Anti Infective Drugs Market
The global demand for anti-infective drugs is significantly influenced by the rising prevalence of bacterial, viral, and fungal infections faced by healthcare systems around the world. As healthcare professionals confront increasingly complex patterns of resistance, there is a growing reliance on innovative therapies to ensure effective treatment outcomes. This urgent clinical need fosters heightened investment from pharmaceutical companies into research and development, leading to a faster pace of product innovation and broader market access. As a result, hospitals and outpatient facilities prioritize the acquisition of these advanced anti-infective treatments, driving sustained growth across various regions and therapeutic categories, thereby reinforcing a continuous expansion of the market.
Restraints in the Global Anti Infective Drugs Market
The Global Anti-Infective Drugs market faces significant challenges due to escalating antimicrobial resistance, which undermines the effectiveness of current treatments and creates apprehension among healthcare providers and payers. As resistance constrains available treatment options, clinicians might turn to older, more affordable medications, thereby diminishing the demand for innovative products. Regulatory agencies could respond with enhanced approval processes and rigorous post-marketing monitoring, leading to longer development times and heightened costs for pharmaceutical companies. This complex landscape may deter investment, impede the introduction of new treatments, and limit overall market growth, as stakeholders focus on responsible usage and minimizing risks rather than embracing groundbreaking therapies.
Market Trends of the Global Anti Infective Drugs Market
The Global Anti-Infective Drugs market is experiencing a notable trend towards precision therapeutics, emphasizing tailored treatment strategies that align drug mechanisms with the genetic profiles of pathogens and the biomarkers of hosts. This shift is facilitated by advanced sequencing technologies and rapid diagnostic tools, which enhance the timely identification of resistant strains and foster the customization of therapeutic approaches. As a result, clinicians can minimize empirical prescribing, leading to improved patient outcomes and extended lifecycles for anti-infective products. Consequently, manufacturers are increasingly investing in companion diagnostics and developing targeted formulations to align with evolving healthcare needs and public health initiatives globally.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Anti Infective Drugs Market Size by Drug Class Mechanism & CAGR (2026-2033)
- Market Overview
- Antibacterial Drugs
- Beta-Lactams
- Macrolides
- Quinolones
- Antiviral Drugs
- Antifungal Drugs
- Antiparasitic Drugs
Global Anti Infective Drugs Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Oral Formulations
- Parenteral Injections
- Topical Formulations
Global Anti Infective Drugs Market Size by Sales Channel & CAGR (2026-2033)
- Market Overview
- Online
- Offline
Global Anti Infective Drugs Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Direct
- Indirect
Global Anti Infective Drugs Market Size & CAGR (2026-2033)
- North America (Drug Class Mechanism, Route of Administration, Sales Channel, Distribution Channel)
- US
- Canada
- Europe (Drug Class Mechanism, Route of Administration, Sales Channel, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Drug Class Mechanism, Route of Administration, Sales Channel, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Drug Class Mechanism, Route of Administration, Sales Channel, Distribution Channel)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Drug Class Mechanism, Route of Administration, Sales Channel, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Pfizer
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Gilead Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- GlaxoSmithKline
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Merck & Co
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Johnson & Johnson
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Roche Holding
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AstraZeneca
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- AbbVie
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bristol-Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Eli Lilly and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Abbott Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Astellas Pharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sun Pharmaceutical Industries
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cipla
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Dr. Reddy's Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Lupin
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
